BR112023004378A2 - Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina - Google Patents

Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina

Info

Publication number
BR112023004378A2
BR112023004378A2 BR112023004378A BR112023004378A BR112023004378A2 BR 112023004378 A2 BR112023004378 A2 BR 112023004378A2 BR 112023004378 A BR112023004378 A BR 112023004378A BR 112023004378 A BR112023004378 A BR 112023004378A BR 112023004378 A2 BR112023004378 A2 BR 112023004378A2
Authority
BR
Brazil
Prior art keywords
inserts
intracanalicular
cyclosporin
hydrogel
sustained release
Prior art date
Application number
BR112023004378A
Other languages
English (en)
Inventor
D Blizzard Charles
El-Hayek Rami
Goldstein Michael
Jarret Peter
Vanslette Andrew
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Publication of BR112023004378A2 publication Critical patent/BR112023004378A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INSERTOS INTRACANALICULARES BIODEGRADÁVEIS DE LIBERAÇÃO SUSTENTADA QUE COMPREENDEM UM HIDROGEL E UMA CICLOSPORINA. A presente invenção refere-se a insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e ciclosporina, métodos de tratamento ou prevenção de uma doença ocular em um indivíduo com necessidade do mesmo por meio da administração de tais insertos, bem como métodos de fabricação de tais insertos.
BR112023004378A 2020-09-24 2021-09-23 Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina BR112023004378A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082505P 2020-09-24 2020-09-24
US202063124204P 2020-12-11 2020-12-11
PCT/US2021/051724 WO2022066884A1 (en) 2020-09-24 2021-09-23 Sustained release biodegradalbe intracanalicular inserts comprising a hydrogel and cyclosporine

Publications (1)

Publication Number Publication Date
BR112023004378A2 true BR112023004378A2 (pt) 2023-04-04

Family

ID=77913038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004378A BR112023004378A2 (pt) 2020-09-24 2021-09-23 Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina

Country Status (13)

Country Link
US (4) US11291627B1 (pt)
EP (2) EP4344745A3 (pt)
KR (1) KR20230074160A (pt)
CN (1) CN116194091A (pt)
AU (1) AU2021347318A1 (pt)
BR (1) BR112023004378A2 (pt)
CA (1) CA3174203A1 (pt)
DK (1) DK3973952T3 (pt)
ES (1) ES2975148T3 (pt)
IL (1) IL300089A (pt)
MX (1) MX2023003274A (pt)
TW (1) TW202228761A (pt)
WO (1) WO2022066884A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066891A1 (en) * 2020-09-24 2022-03-31 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
BR112023004378A2 (pt) 2020-09-24 2023-04-04 Ocular Therapeutix Inc Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina
WO2024035690A1 (en) * 2022-08-12 2024-02-15 Ocular Therapeutix, Inc. Organogels for sustained drug delivery, methods of preparation and use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4915684A (en) 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5469867A (en) 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US6027470A (en) 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US7347850B2 (en) 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6179862B1 (en) * 1998-08-14 2001-01-30 Incept Llc Methods and apparatus for in situ formation of hydrogels
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
PT1265971E (pt) 1999-12-17 2006-07-31 Biopolymer Products Of Sweden Utilizacao nova de uma composicao bioadesiva compreendendo uma proteina polifenolica
US6982090B2 (en) 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
US20050283109A1 (en) 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
EP1652552B1 (en) 2004-11-02 2008-09-17 Sydney Biotech Pty. Ltd. Extraocular device
CN103393483B (zh) 2006-03-31 2016-08-24 玛提治疗有限公司 用于鼻泪系统的药物释放方法、结构及组合物
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
EP2076557A4 (en) * 2006-08-11 2012-08-29 Starpharma Pty Ltd POLYLYSINE DENDRIMER CONTRAST AGENT
US20080114076A1 (en) 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
US8080593B2 (en) 2006-11-29 2011-12-20 University Of Southern California Reversible thermoresponsive adhesives for implants
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
KR101091028B1 (ko) * 2009-07-02 2011-12-09 아주대학교산학협력단 체내 주입형 하이드로젤 및 이의 생의학적 용도
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CN110124051B (zh) * 2011-06-06 2022-10-21 星法马私人有限公司 大分子
CA2843875C (en) * 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
AU2015360469B2 (en) 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
WO2017015616A1 (en) 2015-07-22 2017-01-26 Envisia Therapeutics, Inc. Ocular protein delivery
JP2018525078A (ja) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 被覆された涙点プラグ
JP2018536484A (ja) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 形状変化する薬物送達デバイス及び方法
CA3038075A1 (en) * 2016-09-23 2018-03-29 Incept, Llc Intracameral drug delivery depots
US10603274B2 (en) * 2016-09-30 2020-03-31 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
CN107550921B (zh) * 2017-08-24 2020-04-14 南京邮电大学 一种纳米颗粒-高分子可注射复合水凝胶双载药体系及其制备方法
DE112018006213A5 (de) * 2018-01-31 2020-09-03 Siemens Healthcare Gmbh Verfahren zur Positionsplanung eines Aufnahmesystems eines medizinischen bildgebenden Geräts und medizinisches bildgebendes Gerät
BR112023004378A2 (pt) * 2020-09-24 2023-04-04 Ocular Therapeutix Inc Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina

Also Published As

Publication number Publication date
WO2022066884A1 (en) 2022-03-31
TW202228761A (zh) 2022-08-01
EP3973952A1 (en) 2022-03-30
EP4344745A3 (en) 2024-10-09
US20220087931A1 (en) 2022-03-24
DK3973952T3 (da) 2024-03-18
CA3174203A1 (en) 2022-03-31
MX2023003274A (es) 2023-04-12
IL300089A (en) 2023-03-01
AU2021347318A1 (en) 2023-03-23
US12109302B2 (en) 2024-10-08
US11779536B2 (en) 2023-10-10
KR20230074160A (ko) 2023-05-26
CN116194091A (zh) 2023-05-30
US20220087932A1 (en) 2022-03-24
US20240041758A1 (en) 2024-02-08
ES2975148T3 (es) 2024-07-03
EP4344745A2 (en) 2024-04-03
US11331267B2 (en) 2022-05-17
US11291627B1 (en) 2022-04-05
US20220202706A1 (en) 2022-06-30
EP3973952B1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
BR112023004378A2 (pt) Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
Agostinone et al. Retinal ganglion cell dendrite pathology and synapse loss: implications for glaucoma
AR070198A1 (es) Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
CO2019006902A2 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
BR112015019546A2 (pt) implante de distribuição de drogas prolongado
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CR8411A (es) Metodo para el tratamiento de la enfermedad asociada con adamts-5
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
BR112016001289A2 (pt) pancreatina de alta atividade (ha-pancreatina), composição farmacêutica de alta potência, processo para preparação da ha-pancreatina com atividade de lipase específica de, pelo menos, cerca de 120 ui usp/mg e método de tratamento de um paciente que apresenta uma condição fisiológica associada à insuficiência enzimática pancreática
CO2022016196A2 (es) Composiciones de arni del factor b del complemento (cfb) y métodos de uso de las mismas
PE20211304A1 (es) Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
Mura et al. Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
CL2020001344A1 (es) Tratamiento antisentido del síndrome de angelman.
CL2023000853A1 (es) Compuestos y composiciones como moduladores de señalización tlr
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica